These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27133732)

  • 1. Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study.
    Wisinski KB; Xu W; Tevaarwerk AJ; Saha S; Kim K; Traynor A; Dietrich L; Hegeman R; Patel D; Blank J; Harter J; Burkard ME
    Clin Breast Cancer; 2016 Aug; 16(4):256-61. PubMed ID: 27133732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer.
    McNamara KM; Oguro S; Omata F; Kikuchi K; Guestini F; Suzuki K; Yang Y; Abe E; Hirakawa H; Brown KA; Takanori I; Ohuchi N; Sasano H
    Breast Cancer Res Treat; 2017 Jan; 161(2):213-227. PubMed ID: 27848152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
    Hinsche O; Girgert R; Emons G; Gründker C
    Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.
    Schüler-Toprak S; Häring J; Inwald EC; Moehle C; Ortmann O; Treeck O
    BMC Cancer; 2016 Dec; 16(1):951. PubMed ID: 28003019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
    Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
    Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
    Ellis MJ; Gao F; Dehdashti F; Jeffe DB; Marcom PK; Carey LA; Dickler MN; Silverman P; Fleming GF; Kommareddy A; Jamalabadi-Majidi S; Crowder R; Siegel BA
    JAMA; 2009 Aug; 302(7):774-80. PubMed ID: 19690310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
    Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
    Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
    Rayson D; Lupichuk S; Potvin K; Dent S; Shenkier T; Dhesy-Thind S; Ellard SL; Prady C; Salim M; Farmer P; Allo G; Tsao MS; Allan A; Ludkovski O; Bonomi M; Tu D; Hagerman L; Goodwin R; Eisenhauer E; Bradbury P
    Breast Cancer Res Treat; 2016 May; 157(1):109-16. PubMed ID: 27116183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer.
    Alexandrova E; Lamberti J; Saggese P; Pecoraro G; Memoli D; Cappa VM; Ravo M; Iorio R; Tarallo R; Rizzo F; Collina F; Cantile M; Bonito MD; Botti G; Nassa G; Weisz A; Giurato G
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells.
    Shanle EK; Zhao Z; Hawse J; Wisinski K; Keles S; Yuan M; Xu W
    Mol Endocrinol; 2013 Oct; 27(10):1762-75. PubMed ID: 23979844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
    Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.
    Wang J; Zhang C; Chen K; Tang H; Tang J; Song C; Xie X
    Breast Cancer Res Treat; 2015 Jul; 152(2):255-69. PubMed ID: 26070269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
    BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
    Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
    J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.
    Salahuddin A; Ghanem H; Omran GA; Helmy MW
    Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.
    Finn RS; Bengala C; Ibrahim N; Roché H; Sparano J; Strauss LC; Fairchild J; Sy O; Goldstein LJ
    Clin Cancer Res; 2011 Nov; 17(21):6905-13. PubMed ID: 22028489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
    Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of ERβ hijacks the splicing machinery to trigger R-loop formation in triple-negative breast cancer.
    Wang D; Tang M; Zhang P; Yang K; Huang L; Wu M; Shen Q; Yue J; Wang W; Gong Y; Warner M; Dai L; He H; Yang Z; Gustafsson JA; Zhou S
    Proc Natl Acad Sci U S A; 2024 Mar; 121(13):e2306814121. PubMed ID: 38513102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
    Yardley DA; Arrowsmith ER; Daniel BR; Eakle J; Brufsky A; Drosick DR; Kudrik F; Bosserman LD; Keaton MR; Goble SA; Bubis JA; Priego VM; Pendergrass K; Manalo Y; Bury M; Gravenor DS; Rodriguez GI; Inhorn RC; Young RR; Harwin WN; Silver C; Hainsworth JD; Burris HA
    Breast Cancer Res Treat; 2017 Aug; 164(3):649-658. PubMed ID: 28508185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis.
    Reese JM; Bruinsma ES; Nelson AW; Chernukhin I; Carroll JS; Li Y; Subramaniam M; Suman VJ; Negron V; Monroe DG; Ingle JN; Goetz MP; Hawse JR
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):E9580-E9589. PubMed ID: 30257941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.